Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus

Cancer Gene Therapy

Volumn 12, Issue 3, 2005, Pages 295-303

  Bian, Huijie ^a,c   Fournier, Philippe ^a   Moormann, Rob ^b   Peeters, Ben ^b   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bispecific; Enhanced green fluorescent protein; Newcastle disease virus; Targeted

Indexed keywords

GREEN FLUORESCENT PROTEIN; HEMAGGLUTININ; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; SIALIDASE; VIRUS RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC SELECTION; HYBRIDOMA; IN VITRO STUDY; LEUKEMIA CELL LINE; MOLECULAR CLONING; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ANIMALS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; FLUORESCEINS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HN PROTEIN; HUMANS; INTERLEUKIN-2; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEWCASTLE DISEASE VIRUS; SUCCINIMIDES;

NEWCASTLE DISEASE VIRUS;

EID: 14644423954     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700774     Document Type: Article

References (40)

1. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved anti-tumor immune memory. Cancer Immunol Immunother. 2004 Oct 30.
2. Liang W, Wang H, Sun TM, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003;9:495-498.
3. Batliwalla FM, Bateman BA, Serrano D, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8T cell repertoire. Mol Med. 1998;4:783-794.
4. Schirrmacher V, Ahlert T, Probstle T, et al. Immunization with virus-modified tumor cells. Semin Oncol. 1998;25:677-696.
5. Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol. 1997;15:1354-1366.
6. Ockert D, Schirrmacher V, Beck N, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996;2:21-28.
7. Lorence RM, Pecora AL, Major PP, et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther. 2003;5:618-624.
8. Zhao H, Peeters BP. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol. 2003;84(Part 4):781-788.
9. Al-Garib SO, Gielkens AL, Gruys E, Peeters BP, Koch G. Tissue tropism in the chicken embryo of non-virulent and virulent Newcastle diseases strains that express green fluorescence protein. Avian Pathol. 2003;32:591-596.
10. Engel-Herbert I, Werner O, Teifke JP, Mebatsion T, Mettenleiter TC, Romer-Oberdorfer A. Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein. J Virol Methods. 2003;108:19-28.
11. Nagai Y, Hamaguchi M, Toyoda T. Molecular biology of Newcastle disease virus. Prog Vet Microbio Immunol. 1989;5:16-64.
12. Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol. 2000;16:1-15.
13. Huang Z, Elankumaran S, Panda A, Samal SK. Recombinant Newcastle disease virus as a vaccine vector. Poult Sci. 2003;82:899-906.
14. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol. 2002;21:85-93.
15. Zeng J, Fournier P, Schirrmacher V. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology. 2002;97:19-30.
16. Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol. 2001;18:945-952.
17. Barker SD, Dmitriev IP, Nettelbeck DM, et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Therapy. 2003;10:1198-1204.
18. Jongmans W, van den Oudenalder K, Tiemessen DM, et al. Targeting of adenovirus to human renal cell carcinoma cells. Urology. 2003;62:559-565.
19. Nicklin SA, Baker AH. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther. 2002;2:273-293.
20. Horiuchi S, Koyanagi Y, Tanaka Y, et al. Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism. Immunology. 1997;91:28-34.
21. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol. 2002;22:51-56.
22. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA. 2003;100:1891-1895.
23. Peeters BP, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol. 1999;73:5001-5009.
24. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther. 2002;9:961-966.
25. Palese P, Zheng H, Engelhardt OG, Pleschka S, Garcia-Sastre A. Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci USA. 1996;93:11354-11358.
26. Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol. 2000;74:928-936.
27. Bucheit AD, Kumar S, Grote DM, et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther. 2003;7:62-72.
28. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood. 2003;101:2557-2562.
29. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol. 2001;75:2087-2096.
30. Krishnamurthy S, Huang Z, Samal SK. Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology. 2000;278:168-182.
31. Romer-Oberdorfer A, Mundt E, Mebatsion T, Buchholz UJ, Mettenleiter TC. Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol. 1999;80(Part 11):2987-2995.
32. Huang Z, Krishnamurthy S, Panda A, Samal SK. High-level expression of a foreign gene from the most 3′-proximal locus of a recombinant Newcastle disease virus. J Gen Virol. 2001;82(Part 7):1729-1736.
33. Nettelbeck DM, Miller DW, Jerome V, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther. 2001;3:882-891.
34. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol. 1999;17:181-186.
35. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 1998;58:5738-5748.
36. Boerger AL, Snitkovsky S, Young JA. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci USA. 1999;96:9867-9872.
37. Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest. 1985;76:446-453.
38. Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V, Beckhove P. T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med. 2003;9:526-534.
39. Fournier P, Zeng J, Schirrmacher V. Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. Int J Oncol. 2003;23:673-680.
40. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732-738.